Eosinophilia in mast cell disease

Immunology and Allergy Clinics of North America

Volumn 34, Issue 2, 2014, Pages 357-364

  Kovalszki, Anna ^a   Weller, Peter F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chronic eosinophilic leukemia (CEL); Eosinophilia; FIP1L1 PDGFRA fusion; Hypereosinophilic syndrome; Imatinib; Systemic mastocytosis; Tryptase

Indexed keywords

CD2 ANTIGEN; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 9; MIDOSTAURIN; OMALIZUMAB; STEM CELL FACTOR RECEPTOR; TRYPTASE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CELL LINEAGE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; EOSINOPHIL; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC LEUKEMIA; GAIN OF FUNCTION MUTATION; GENE MUTATION; HETEROZYGOSITY; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAST CELL; MAST CELL DEGRANULATION; MASTOCYTOSIS; MEDIATOR RELEASE; ONCOGENE C KIT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; SYSTEMIC MASTOCYTOSIS; BONE MARROW; CELL COMMUNICATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MASTOCYTOSIS, SYSTEMIC; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BONE MARROW; CELL COMMUNICATION; EOSINOPHILS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPEREOSINOPHILIC SYNDROME; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; STEM CELL FACTOR;

EID: 84898787686     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2014.01.013     Document Type: Review

References (36)

1. Metcalfe D.D. Mastocytosis. Middleton's allergy principles and practice 2014, vol. 2:1224-1236. Saunders Elsevier, Philadelphia. 8th edition.
2. Gotlib J., Akin C. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. Semin Hematol 2012, 49(2):128-137.
3. Klion A.D., Weller P.F. Eosinophilia and eosinophil related disorders. Middleton's allergy principles and practice 2014, vol. 2:1205-1223. Saunders Elsevier, Philadelphia. 8th edition.
4. Otani I.M., Anilkumar A.A., Newbury R.O., et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. JAllergy Clin Immunol 2013, 131(6):1576-1582.
5. Kovalszki A., Sheikh J., Weller P.F. Eosinophils and eosinophilia. Clinical immunology principles and practice 2013, vol. 1:298-309. Elsevier Saunders, Philadelphia. 4th edition.
6. Elishmereni M., Alenius H.T., Bradding P., et al. Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival invitro. Allergy 2011, 66(3):376-385.
7. Elishmereni M., Bachelet I., Nissim Ben-Efraim A.H., et al. Interacting mast cells and eosinophils acquire an enhanced activation state invitro. Allergy 2013, 68(2):171-179.
8. Jarjour N.N., Calhoun W.J., Schwartz L.B., et al. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis 1991, 144(1):83-87.
9. Rasp G., Hochstrasser K. Tryptase in nasal fluid is a useful marker of allergic rhinitis. Allergy 1993, 48(2):72-74.
10. Bargagli E., Bigliazzi C., Leonini A., et al. Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia. Clin Sci 2005, 108(3):273-276.
11. Abonia J.P., Blanchard C., Butz B.B., et al. Involvement of mast cells in eosinophilic esophagitis. JAllergy Clin Immunol 2010, 126(1):140-149.
12. Kirsch R., Bokhary R., Marcon M.A., et al. Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. JPediatr Gastroenterol Nutr 2007, 44(1):20-26.
13. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. JAllergy Clin Immunol 2009, 124(6):1319-1325.e3.
14. Butterfield J.H., Weiler C.R. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res 2012, 36(2):192-197.
15. Cardet J.C., Akin C., Lee M.J. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother 2013, 14(15):2033-2045.
16. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. JAllergy Clin Immunol 2007, 120(3):680-687.
17. Robyn J., Lemery S., McCoy J.P., et al. Multilineage involvement of the fusion genein patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006, 132(3):286-292.
18. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset ofpatients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101(12):4660-4666.
19. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004, 103(2):473-478.
20. Akin C., Metcalfe D.D. The biology of Kit in disease and the application of pharmacogenetics. JAllergy Clin Immunol 2004, 114(1):13-19. [quiz: 20].
21. Valent P., Akin C., Sperr W.R., et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005, 46(1):35-48.
22. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25(7):603-625.
23. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114(18):3769-3772.
24. Kristensen T., Vestergaard H., Moller M.B. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. JMol Diagn 2011, 13(2):180-188.
25. Akin C., Kirshenbaum A.S., Semere T., et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000, 28(2):140-147.
26. Yavuz A.S., Lipsky P.E., Yavuz S., et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002, 100(2):661-665.
27. Florian S., Esterbauer H., Binder T., et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006, 30(9):1201-1205.
28. Valent P., Sperr W.R., Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010, 116(26):5812-5817.
29. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. NEngl J Med 1992, 326(9):619-623.
30. Cools J., DeAngelo D.J., Gotlib J., et al. Atyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. NEngl J Med 2003, 348(13):1201-1214.
31. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31(8):686-692.
32. Rothenberg M.E., Klion A.D., Roufosse F.E., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. NEngl J Med 2008, 358(12):1215-1228.
33. Pavord I.D., Korn S., Howarth P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380(9842):651-659.
34. Corren J., Casale T., Deniz Y., et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. JAllergy Clin Immunol 2003, 111(1):87-90.
35. Chiang D.T., Clark J., Casale T.B. Omalizumab in asthma: approval and postapproval experience. Clin Rev Allergy Immunol 2005, 29(1):3-16.
36. Carter M.C., Robyn J.A., Bressler P.B., et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. JAllergy Clin Immunol 2007, 119(6):1550-1551.